Ocular Therapeutix (OCUL) Amortization of Deferred Charges (2013 - 2026)

Ocular Therapeutix's Amortization of Deferred Charges history runs 14 years deep, the most recent figure standing at $1.4 million for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges fell 3.83% year-over-year to $1.4 million in Q1 2026; TTM through Mar 2026 was $3.3 million, a 4.37% increase from a year earlier, with the FY2025 full-year figure at $3.4 million, down 9.03% from the prior year.
• Amortization of Deferred Charges rose to $1.4 million in Q1 2026 per OCUL's latest filing, from $495000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $2.1 million in Q3 2023 and bottomed at $495000.0 in Q4 2025.
• The 5-year median for Amortization of Deferred Charges is $1.2 million (2022), against an average of $1.1 million.
• Across the five-year window, Amortization of Deferred Charges surged 69.14% in 2023 and tumbled 70.03% in 2024, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $1.2 million in 2022, then advanced by 25.55% to $1.6 million in 2023, then plunged by 62.91% to $576000.0 in 2024, then slipped by 14.06% to $495000.0 in 2025, then jumped by 178.99% to $1.4 million in 2026.
• Per Business Quant, the three latest OCUL Amortization of Deferred Charges figures stand at $1.4 million (Q1 2026), $495000.0 (Q4 2025), and $758000.0 (Q3 2025).